• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Advocacy
      • Fundamental Rights of People with ALS/MND and Caregivers
      • Advocacy Toolkit
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
      • Expanded Access
    • Care Services
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Clinical Trial
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award Nomination
      • Allied Health Professional Award Nomination
      • Humanitarian Award Nomination
  • Members
    • Member Registration
    • Forgot Password

Orphazyme – Arimoclomol

Orphazyme – Arimoclomol

Background

Arimoclomol is an oral capsule drug that enhances a mechanism known as the heat shock response. When a cell of the body is exposed to stress or damage, the proteins required for the cell’s normal functions can change their shape or “fold” and either lose their ability to do their job or become toxic. Cells protect themselves from this misfolding of proteins by stimulating production of heat shock proteins (Hsps) that are designed to manage the proper protein refolding.

Misfolded and clumped proteins have long been a hallmark of ALS/MND and it is believed that these may contribute to multiple disease processes. Unlike other cells, neurons, and particularly motor neurons, have an impaired ability to produce an effective heat shock response. Therefore, drugs that can enhance the production of Hsps may have therapeutic value in ALS/MND.

Arimoclomol was first published to have an effect on elevating Hsps and delaying disease progression in an ALS/MND mouse model in 2004. In 2008, it was tested for safety, tolerability and pharmacokinetics in 84 people living with ALS/MND by the Northeast ALS Consortium (NEALS), indicating it could be dosed safely up to three times daily at 100 mg per dose and that it effectively crossed the blood-brain barrier. A follow up academic (non pharma, investigator-initiated) clinical trial led by Dr. Michael Benatar, examined arimoclomol in a double-blind, placebo-controlled study of 38 people with fast-progressing ALS caused by SOD1 mutations at 200 mg/day over 12 months. Again arimoclomol was deemed safe and tolerable but the indication that the drug may slow down disease progression and prolong survival was not statistically significant, and they could not draw conclusions about its efficacy in ALS/MND. It was considered safe and well-tolerated, with only one person stopping treatment due to skin rash.

Orphazyme was founded in Denmark in 2009 based on work demonstrating that Hsps could also correct an abnormality in a cellular structure called the lysosome, implicated in diseases called lysosomal storage diseases. In advancing arimoclomol as an Hsp-inducing drug for these diseases, the company also initiated an ALS program, using the substantial groundwork to initiate a phase 3 clinical trial.

The multicenter, randomized, double-blind, placebo-controlled study was started in 2018, enrolling 245 people living with ALS, with a 2:1 treatment to placebo ratio and studied over 76 weeks. A measure called the Combined Assessment of Function and Survival was used as the primary means of determining if arimoclomol is effective in ALS, while other common measures like ALSFRS-R, survival and slow vital capacity (SVC) were also evaluated. Arimoclomol is an oral capsule that was taken three times daily for the duration of the study.

Trial Results

On May 7, 2021, an Orphazyme press release stated that the “pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival”. This indicates that arimoclomol will not be further pursued as a treatment for ALS/MND. A forthcoming publication of the data, including additional biomarker work, is expected.

Recommendation

Orphazyme is expected to communicate an initial interpretation of their data in press release form, sometime in Q2 of 2021. The SAC will provide more comment at that time.

 

International Alliance of ALS/MND Associations
May 2021

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Angie Bordaen, Diagnosed 2014 - ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014 – ALS Liga België, Belgium

  • Roxana Canova, Diagnosed 2012 - Asociación ELA Argentina

    Roxana Canova, Diagnosed 2012 – Asociación ELA Argentina

  • Steven Spencer, Diagnosed 2014 - MND New Zealand

    Steven Spencer, Diagnosed 2014 – MND New Zealand

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

  • Elizabeth-y-Juvenal-v2

    Elizabeth-y-Juvenal-v2

  • Elkin-Ramiro-Gaviria-Muñoz-diagnosed-Dec-2018-v3

    Elkin-Ramiro-Gaviria-Muñoz-diagnosed-Dec-2018-v3

  • Conny van der Meijden, Diagnosed 2001 - ALS Netherlands

    Conny van der Meijden, Diagnosed 2001 – ALS Netherlands

  • Cath

    Cath

  • ALS-0571

    ALS-0571

  • MND-Robbie-Caliste

    MND-Robbie-Caliste

  • Dorette Lüdi, Diagnosed 2014 - ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 – ALS Schweiz, Switzerland

  • Phil-Rossall-MND-Association

    Phil-Rossall-MND-Association

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Ailsa Malcolm-Hutton, Diagnosed 2013 - MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013 – MND Association of England, Wales and N Ireland

  • Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

  • Duncan Bayly - MND Australia

    Duncan Bayly – MND Australia

  • Fabio-Carvalho3

    Fabio-Carvalho3

  • Ann-Nicol

    Ann-Nicol

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Joy Blakeley, Diagnosed 2017 - MND Australia

    Joy Blakeley, Diagnosed 2017 – MND Australia

  • David-Bishop-copy-2

    David-Bishop-copy-2

  • Eddy LeFrançois, Diagnosed 1992 - ALS Canada

    Eddy LeFrançois, Diagnosed 1992 – ALS Canada

  • IMG_3993

    IMG_3993

  • Marcel R. Wernard, Diagnosed 2016 - ALS Patients Connected, The Netherlands

    Marcel R. Wernard, Diagnosed 2016 – ALS Patients Connected, The Netherlands

  • Mary Thomas, Diagnosed 2013 - MND Australia

    Mary Thomas, Diagnosed 2013 – MND Australia

  • Margreth Burger-Saile, Diagnosed 2011 - ALS Schweiz, Switzerland

    Margreth Burger-Saile, Diagnosed 2011 – ALS Schweiz, Switzerland

  • Fabio-Correia-2

    Fabio-Correia-2

  • final3878

    final3878

  • David Watson, MND Scotland, Diagnosed 2018, Scotland

    David Watson, MND Scotland, Diagnosed 2018, Scotland

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Luis-Antonio-Pimenta-Lima-ABrELA

    Luis-Antonio-Pimenta-Lima-ABrELA

  • Monica Soriano, Diagnosed 2011 - Asociación ELA Argentina

    Monica Soriano, Diagnosed 2011 – Asociación ELA Argentina

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • Francisco Perez Palop, Diagnosed 2013 - FUNDELA, Spain

    Francisco Perez Palop, Diagnosed 2013 – FUNDELA, Spain

  • 55405686-609D-4060-BB1E-8697F36FA62F

    55405686-609D-4060-BB1E-8697F36FA62F

  • Chris McCauley, Diagnosed 2015 - ALS Canada

    Chris McCauley, Diagnosed 2015 – ALS Canada

  • Charlie “Hark” Dourney, Diagnosed 2007 - Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 – Hark ALS, USA

  • 9B63A612-09B4-453E-8430-B76DB0AB5196

    9B63A612-09B4-453E-8430-B76DB0AB5196

  • roy

    roy

  • Kirsten Harley, Diagnosed 2013 - Australia

    Kirsten Harley, Diagnosed 2013 – Australia

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Mike Rannie, ALS Canada, Diagnosed 2017, Canada

    Mike Rannie, ALS Canada, Diagnosed 2017, Canada

  • pALS-Guido-De-Mets-ALS-Liga-Belgium

    pALS-Guido-De-Mets-ALS-Liga-Belgium

  • Carlos Gomez Matallanas, Diagnosed 2014 - FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 – FUNDELA, Spain

  • Willi-Klein

    Willi-Klein

  • 20200117_214643

    20200117_214643

  • Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

Learn more about the March of Faces

Latest Tweets

  • Just now

Subscribe to our Bi-Monthly Newsletter

Fill out the form below to subscribe to the Alliance's bi-monthly newsletter, packed with updates from members associations from around the world!

Footer

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.

  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2022 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login